Skip to main content Skip to journal navigation menu Skip to site footer
contact@ukscip.com
Case Report

Durable complete response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma

Kenta Takayasu ,  Koei Muguruma ,  Hidefumi Kinoshita
    Received: 05 September 2024
    Published: 14 January 2022

    Abstract

    Immune checkpoint inhibitors, which promote or suppress the anti-tumor immune response, are becoming the mainstay of cancer treatment. In 2018, CheckMate 214 study showed a higher response rate with ipilimumab and nivolumab combination therapy compared to conventional therapy for advanced renal cell carcinoma. We report a case of complete response and durable response for two years to ipilimumab and nivolumab combination therapy in a patient with postoperative renal cancer recurrence that caused immune-related adverse events such as interstitial pneumonia and hepatotoxicity.

    Keywords

    References

    1. 1. Furukawa F. The Nobel Prize in Physiology or Medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends in Immunotherapy 2018; 2(1). doi: 10.24294/ti.v2.i3.1065
    2. 2. Seidel JA, OtsukaA, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends in Immunotherapy 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20
    3. 3. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in sdvanced renal-cell carcinoma. New England Journal of Medicine 2018; 378(14): 1277–1290. doi: 10.1056/NEJMoa1712126
    4. 4. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5(6): e001079. doi: 10.1136/esmoopen-2020-001079
    5. 5. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology 1999; 17(8): 2530–2540. doi: 10.1200/JCO.1999.17.8.2530
    6. 6. Iacovelli R, Alesini D, Palazzo A, et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews 2014; 40(2): 271–275. doi: 10.1016/j.ctrv.2013.09.003
    7. 7. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine 2015; 373(19): 1803–1813. doi: 10.1056/NEJMoa1510665
    8. 8. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. The Journal of Immunology 2014; 192(12): 5451–5458. doi: 10.4049/jimmunol.1490019
    9. 9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2019; 30(5): 706–720. doi: 10.1093/annonc/mdz056
    10. 10. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends in Immunotherapy 2020; 4(1): 18–26. doi: 10.24294/ti.v4.i1.606
    ×